Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Serum NSE is an independent risk factor for positive PD-L1 in breast cancer patients
1Department of Clinical Laboratory, The 1st Medical Centre, Chinese PLA General Hospital, 100853 Beiing, China
DOI: 10.22514/ejgo.2024.092 Vol.45,Issue 5,October 2024 pp.34-41
Submitted: 01 December 2022 Accepted: 16 May 2023
Published: 15 October 2024
*Corresponding Author(s): Jingzhu Nan E-mail: nanjingzhu0885@hotmail.com
† These authors contributed equally.
To investigate the relationship between the level of serum tumor markers and the expression of programmed cell death-ligand-1 (PD-L1) in breast cancer patients, and to explore the diagnostic value of serum tumor markers for the positive expression of PD-L1. The basic information, preoperative serum tumor markers and postoperative pathological results of 139 patients with breast cancer who received treatment for the first time in People’s Liberation Army (PLA) General Hospital between 2019 and 2020 were collected. The relationship between preoperative tumor markers and postoperative pathological PD-L1 positive expression in breast cancer patients was analyzed, and binary and multivariate Logistic regression model was established to explore the predictive ability of various tumor markers for the positive expression of PD-L1. The serum level of neuron-specific enolase (NSE) was positively correlated with the expression of PD-L1. The level of NSE was statistically different between the two groups of PD-L1 (PD-L1 (0%) and PD-L1 (≥1%)) (p < 0.05). Serum NSE level was better than carbohydrate antigen15-3 (CA15-3) in predicting the positive expression of PD-L1. The sensitivity and specificity were 0.786 and 0.545 when the cutoff value is 11.28, respectively. The area under receiver operating characteristic (ROC) curve (AUC) = 0.711. Serum NSE is an independent risk factor for positive expression of PD-L1.
PD-L1; NSE; Breast cancer
Xuemei Wei,Xu Zhang,Lin Zhu,Jingzhu Nan. Serum NSE is an independent risk factor for positive PD-L1 in breast cancer patients. European Journal of Gynaecological Oncology. 2024. 45(5);34-41.
[1] Katsura C, Ogunmwonyi I, Kankam HK, Saha S. Breast cancer: presentation, investigation and management. British Journal of Hospital Medicine. 2022; 83: 1–7.
[2] Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. The Breast. 2022; 66: 15–23.
[3] Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. American Journal of Cancer Research. 2020; 10: 727–742.
[4] Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Advances in Experimental Medicine and Biology. 2020; 1248: 33–59.
[5] Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death & Disease. 2020; 11: 955.
[6] Li J, Ao N, Qiao DB, Zhang XR. Correlation between PD-L1 expression and clinicopathological features and prognosis of breast cancer. Chinese Journal of Cancer Prevention and Treatment. 2018; 25: 1395–1402. (In Chinese)
[7] Huang W, Ran R, Shao B, Li H. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Research and Treatment. 2019; 178: 17–33.
[8] Stovgaard ES, Dyhl-Polk A, Roslind A, Balslev E, Nielsen D. PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. Breast Cancer Research and Treatment. 2019; 174: 571–584.
[9] Gonzalez‐Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immune-oncology biomarkers in breast cancer clinical trials and daily practice. The Journal of Pathology. 2020; 250: 667–684.
[10] Pernas S, Tolaney SM. Clinical trial data and emerging strategies: HER-2-positive breast cancer. Breast Cancer Research and Treatment. 2022; 193: 281–291.
[11] Vranic S, Cyprian FS, Gatalica Z, Palazzo J. PD-L1 status in breast cancer: current view and perspectives. Seminars in Cancer Biology. 2021; 72: 146–154.
[12] Huang WY, Yang XH. Correlation of PD-1 and PD-L1 expression with tumor infiltrating lymphocytes and clinicopathological indicators in triple negative breast cancer. Journal of Modern Oncology. 2021; 30: 2181–2185. (In Chinese)
[13] Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, et al. PD-L1 (B7-H1) expression and the immune microenvironment in primary and metastatic breast carcinomas. Human Pathology. 2016; 47: 52–63.
[14] Li X, Li M, Lian Z, Zhu H, Kong L, Wang P, et al. Prognostic role of programmed death ligand-1 expression in breast cancer: a systematic review and meta-analysis. Targeted Oncology. 2016; 11: 753–761.
[15] Emens LA. Breast cancer immunotherapy: facts and hopes. Clinical Cancer Research. 2018; 24: 511–520.
[16] Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Letters. 2020; 468: 72–81.
[17] Cha J, Chan L, Li C, Hsu JL, Hung M. Mechanisms controlling PD-L1 expression in cancer. Molecular Cell. 2019; 76: 359–370.
[18] Heery CR, O’Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. The Lancet Oncology. 2017; 18: 587–598.
[19] Dirix L, Takacs I, Nikolinakos P, Jerusalem G, Arkenau H-T, Hamilton E, et al. Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. Cancer research. 2016; 76: S1-04.
[20] Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2022; 20: 691–722.
[21] Xu C, Luo Y, Li S, Li Z, Jiang L, Zhang G, et al. Multifunctional neuron-specific enolase: its role in lung diseases. Bioscience Reports. 2019; 39: BSR20192732.
[22] Li L, Zhang Z, Hu Y. Neuron-specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors. Medicine. 2021; 100: e27029.
[23] Yu XX, Zhang LL, Zhang XX, Jin H. Expression of serum prostate specific antigen, carbohydrate antigen 153 and neuron-specific enolase in breast cancer and their correlation with neovascularization and prognosis. Modern Medicine and Health Research Electronic Journal. 2022; 6: 14–17.
[24] Wu CR, Tang SN, Ye HZ. Application of combined detection of breast tumor markers in postoperative monitoring of breast cancer patients. Laboratory Medicine and Clinic. 2022; 19: 2323–2330. (In Chinese)
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.
Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.
JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.
Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.
BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Top